Gabapentin Clinical Edit Criteria



Drug/Drug Class:

Gabapentin

Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. This clinical edit criteria applies to all Superior HealthPlan STAR, STAR Health, STAR Kids, STAR+PLUS and CHIP members. Superior has adjusted the clinical criteria to ease the prior authorization process regarding this clinical edit. Criteria for Neurontin agents will not be implemented. Criteria for Gralise and Horizant agents will be implemented as originally written. Adjusted criteria steps are outlined/highlighted in yellow.

The original clinical edit can be referenced at the VDP website located at https://paxpress.txpa.hidinc.com/neurontin.pdf.

Clinical Edit Information Included in this Document:

Neurontin (gabapentin)

Gralise (gabapentin extended release)

- Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria.
- Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules.
- Logic diagram: a visual depiction of the clinical edit criteria logic.
- Diagnosis codes or drugs in step logic: a list of diagnosis codes or drug information and additional step logic, claims and lookback period information.
- Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable.

Horizant (gabapentin enacarbil)

- Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria.
- Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules.
- Logic diagram: a visual depiction of the clinical edit criteria logic.
- Diagnosis codes or drugs in step logic: a list of diagnosis codes or drug information and additional step logic, claims and lookback period information.
- Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable.

Please note: All tables are provided by original Texas VDP Gabapentin Edit.

SHP_202410716C Page **1** of **13**

Drugs Requiring Prior Authorization Gralise (gabapentin extended release):

The listed GCNs may not be an indication of Texas Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.


| Drugs Requiring | Prior Authorization |
|--------------------------|---------------------|
| Label Name | GCN |
| GRALISE ER 300 MG TABLET | 30295 |
| GRALISE ER 600 MG TABLET | 30296 |

Superior HealthPlan Clinical Criteria Logic Gralise (gabapentin extended release):

| 1. Is the client less than (<) 18 years of age? | |
|--|-----------|
| [] Yes (Deny) | |
| [] No (Go to #2) | |
| 2. Is the incoming request for a dose less than or equal to (≤) 1,800 mg per day? | |
| [] Yes (Go to #3) | |
| [] No (Deny) | |
| 3. Does the client have a diagnosis of postherpetic neuralgia in the last 730 days? | |
| [] Yes (Go to #4) | |
| [] No (Deny) | |
| 4. Does the client have a diagnosis of severe renal impairment or hemodialysis in the last 3 | 365 days? |
| [] Yes (Deny) | |
| [] No (Approve – 365 days) | |

IP_202410716C Page **3** of **13**

Superior HealthPlan Clinical Edit Logic Diagram Gralise (gabapentin extended release):



Page 4 of 13

Clinical Criteria Supporting Tables Gralise (gabapentin extended release):

| Step 3 (diagnosis of postherpetic neuralgia) Required diagnosis: 1 Look back timeframe: 730 days | |
|--|---|
| ICD-10 Code | Description |
| B0221 | POSTHERPETIC GENICULATE GANGLIONITIS |
| B0222 | POSTHERPETIC TRIGEMINAL NEURALGIA |
| B0223 | POSTHERPETIC POLYNEUROPATHY |
| B0224 | POSTHERPETIC MYELITIS |
| B0229 | OTHER POSTHERPETIC NERVOUS SYSTEM INVOLVEMENT |

| Step 4 (diagnosis of severe renal impairment or hemodialysis) Required diagnosis: 1 Look back timeframe: 365 days | |
|---|--|
| ICD-10 Code | Description |
| N184 | CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) |
| N185 | CHRONIC KIDNEY DISEASE, STAGE 5 |
| N186 | END STAGE RENAL DISEASE |
| CPT Code | Description |
| 90940 | HEMODIALYSIS ACCESS STUDY |
| 90941 | HEMODIALYSIS, INITIAL OR ACUTE (EG, ACUTE RENAL FAILURE OR INTOXICAT; PAT OVER 40 KG |
| 90942 | HEMODIALYSIS, INITIAL OR ACUTE (EG, ACUTE RENAL FAILURE OR INTOXICAT: PAT 21-40 KG |
| 90943 | HEMODIAL, INITIAL OR ACUTE (EG, ACUTE RENAL FAILURE OR INTOXICAT; PAT OVER 40 KG |
| 90944 | HEMODIAL, INITIAL OR ACUTE (EG, ACUTE RENAL FAILURE OR INTOXICAT; PAT UNDER 10 KG |
| 90945 | DIALYSIS, ONE EVALUATION |
| 90947 | DIALYSIS, REPEATED EVAL |
| 90951 | ESRD SERV, 4 VISITS P MO, <2 |
| 90952 | ESRD SERV, 2-3 VSTS P MO, <2 |
| 90953 | ESRD SERV, 1 VISIT P MO, <2 |
| 90954 | ESRD SERV, 4 VSTS P MO, 2-11 |
| 90956 | ESRD SRV, 1 VISIT P MO, 2-11 |
| 90957 | ESRD SRV, 4 VSTS P MO, 12-19 |
| 90958 | ESRD SRV 2-3 VSTS P MO 12-19 |

Page **5** of **13**

| Step 4 (diagnosis of severe renal impairment or hemodialysis) Required diagnosis: 1 | |
|--|---|
| | Look back timeframe: 365 days |
| CPT Code | Description |
| 90966 | ESRD HOME PT, SERV P MO, 20+ |
| 90967 | ESRD HOME PT SERV P DAY, <2 |
| 90968 | ESRD HOME PT SRV P DAY, 2-11 |
| 90969 | ESRD HOME PT SRV P DAY 12-19 |
| 90976 | PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE; PATIENT MORE THAN 40 KG |
| 90977 | PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE; PATIENT 21-40 KG |
| 90978 | PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE; PATIENT 11-20 KG |
| 90979 | PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE; PATIENT UNDER 10 KG |
| 90982 | PERITONEAL DIALYSIS FOR (ESRD), MAINT STABI COND, HOSP/OTHER FACIL PER SET; MORE 40 KG |
| 90983 | PERITONEAL DIALYSIS FOR (ESRD), MAINT STABL COND, HOSP/OTHER FAC PER SET; PATIENT 21-40 KG |
| 90984 | PERITONEAL DIALYSIS FOR (ESRD), MAINT STABI COND, HOSP/OTHER FAC PER SET; PATIENT 11-20 KG |
| 90985 | PERITONEAL DIALYSIS FOR (ESRD), MAINT STABI COND, HOSP/OTHER FAC PER SET; PATIENT UNDER 10K |
| 90990 | HEMODIALYSIS TRAINING AND/OR COUNSELING |
| 90991 | HOME HEMODIALYSIS CARE, OUTPAT, SERV PROVID BY PHYSI RESPONS FOR TOTAL CARE |
| 90992 | PERITONEAL DIALYSIS TRAINING AND/OR COUNSELING (MEDICARE ONLY) |
| 90994 | SUPERVISION OF CHRONIC AMBPERITONEAL DIAL (CAPD),HOME/OUT-PATIENT,MONTHLY |

Page **6** of **13**

Drugs Requiring Prior Authorization Horizant (gabapentin enacarbil):

The listed GCNs may not be an indication of Texas Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.


| Drugs Requiring | Prior Authorization |
|---------------------------|---------------------|
| Label Name | GCN |
| HORIZANT ER 300 MG TABLET | 35819 |
| HORIZANT ER 600 MG TABLET | 29888 |

Superior HealthPlan Clinical Criteria Logic Horizant (gabapentin enacarbil):

| 1. Is th | ne client less than (<) 18 years of age? |
|----------|---|
| | [] Yes (Deny) |
| | [] No (Go to #2) |
| 2. Do | es the client have a diagnosis of restless leg syndrome in the last 730 days? |
| | [] Yes (Go to #3) |
| | [] No (Go to #4) |
| 3. Is th | ne incoming request for a dose less than or equal to (≤) 600 mg per day? |
| | [] Yes (Go to #6) |
| | [] No (Go to #4) |
| 4. Doe | es the client have a diagnosis of postherpetic neuralgia in the last 730 days? |
| | [] Yes (Go to #5) |
| | [] No (Deny) |
| 5. Is th | ne incoming request for a dose less than or equal to (≤) 1,200 mg per day? |
| | [] Yes (Go to #6) |
| | [] No (Deny) |
| 6. Doe | es the client have a diagnosis of alcohol abuse or dependence in the last 180 days? |
| | [] Yes (Deny) |
| | [] No (Approve – 365 days) |

Page **8** of **13**

Superior HealthPlan Clinical Edit Logic Diagram Horizant (gabapentin enacarbil):



Page **9** of **13**

Clinical Criteria Supporting Tables Horizant (gabapentin enacarbil):

| Step 2 (diagnosis of restless leg syndrome) Required diagnosis: 1 Look back timeframe: 730 days | |
|---|------------------------|
| ICD-10 Code | Description |
| G2581 | RESTLESS LEGS SYNDROME |

| Step 4 (diagnosis of postherpetic neuralgia) Required diagnosis: 1 Look back timeframe: 730 days | |
|--|---|
| ICD-10 Code | Description |
| B0221 | POSTHERPETIC GENICULATE GANGLIONITIS |
| B0222 | POSTHERPETIC TRIGEMINAL NEURALGIA |
| B0223 | POSTHERPETIC POLYNEUROPATHY |
| B0224 | POSTHERPETIC MYELITIS |
| B0229 | OTHER POSTHERPETIC NERVOUS SYSTEM INVOLVEMENT |

| Step 6 (diagnosis of alcohol abuse or dependence) Required diagnosis: 1 Look back timeframe: 180 days | |
|---|---|
| ICD-10 Code | Description |
| F1010 | ALCOHOL ABUSE UNCOMPLICATED |
| F10120 | ALCOHOL ABUSE WITH INTOXICATION UNCOMPLICATED |
| F10121 | ALCOHOL ABUSE WITH INTOXICATION DELIRIUM |
| F10129 | ALCOHOL ABUSE WITH INTOXICATION UNSPECIFIED |
| F1014 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED MOOD DISORDER |
| F10150 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS |
| F10151 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS |
| F10159 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER UNSPECIFIED |
| F10180 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED ANXIETY DISORDER |
| F10181 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION |
| F10182 | ALCOHOL ABUSE WITH ALCOHOL-INDUCED SLEEP DISORDER |

SHP_202410716C Page **10** of **13**

| Step 6 (diagnosis of alcohol abuse or dependence) | | |
|---|---|--|
| | Required diagnosis: 1 | |
| | Look back timeframe: 180 days | |
| ICD-10 Code | Description | |
| F10188 | ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDER | |
| F1019 | ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDERS WITH | |
| | UNSPECIFIED ALCOHOL-INDUCED DISORDER | |
| F1020 | ALCOHOL DEPENDENCE UNCOMPLICATED | |
| F10220 | ALCOHOL DEPENDENCE WITH INTOXICATION UNCOMPLICATED | |
| F10221 | ALCOHOL DEPENDENCE WITH INTOXICATION DELIRIUM | |
| F10229 | ALCOHOL DEPENDENCE WITH INTOXICATION UNSPECIFIED | |
| F10230 | ALCOHOL DEPENDENCE WITH WITHDRAWAL UNCOMPLICATED | |
| F10231 | ALCOHOL DEPENDENCE WITH WITHDRAWAL DELIRIUM | |
| F10232 | ALCOHOL DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE | |
| F10239 | ALCOHOL DEPENDENCE WITH WITHDRAWAL UNSPECIFIED | |
| F1024 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED MOOD DISORDER | |
| F10250 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH | |
| | DELUSIONS | |
| F10251 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH | |
| | HALLUCINATIONS | |
| F10259 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH | |
| | HALLUCINATIONS UNSPECIFIED | |
| F1026 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING AMNESTIC | |
| | DISORDER | |
| F1027 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING DEMENTIA | |
| F10280 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY DISORDER | |
| F10281 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION | |
| F10282 | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SLEEP DISORDER | |
| F10288 | ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDER | |
| F1029 | ALCOHOL DEPENDENCE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER | |

SHP_202410716C Page **11** of **13**

Clinical Criteria References:

- 1. 2023 ICD-10-CM Diagnosis Codes. 2022. Available at www.icd10data.com. Accessed on August 15, 2023.
- 2. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2022. Available at www.clinicalpharmacology.com. Accessed on August 15, 2023.
- 3. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on August 15, 2023.
- 4. Neurontin Prescribing Information. New York, New York. Parke-Davis; October 2021.
- 5. Ortega E. Postherpetic neuralgia. In: UpToDate, Shefner JM (Ed), UpToDate, Waltham, MA. Accessed August 15, 2023.
- 6. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice Parameter: Treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology Sept 2004;63(6):959-965. Reaffirmed February 2008.
- 7. Dworkin RH, O'Connor AB, Kent J, et al. International Association for the Study of Pain Neuropathic Pain Special Interest Group. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 2015;23(4):1-8.
- 8. Aurora RN, Kristo DA, Bista SR, et al. The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults An Update for 2012: Practice Parameters with an Evidence-Based Systematic Review and Meta-Analyses. Sleep 2012;35(8):1039-62.
- 9. Gralise (gabapentin) [prescribing information]. Newark, CA: Depomed, Inc; April 2017.
- 10. Winkelman JW, Armstron MJ, Allen RP, etal. Practice Guideline Summary: Treatment of Restless Legs Syndrome in Adults Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology December 2016; 87 (24): 2585- 2593.
- 11. Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC: April 2020.

SHP_202410716C Page **12** of **13**

Publication History:

| Publication | Notes |
|-------------|--|
| 05/20/2019 | Criteria created and cross referenced to VDP criteria. |
| | Updated to include formulary statement (The listed GCNS may not be an indication of TX |
| | Medicaid Formulary coverage. To learn the current formulary coverage, visit |
| | TxVendorDrug.com/formulary/formulary-search.) on each 'Drug Requiring PA' table |
| 04/13/20 | Corrected numbering order for Clinical Edit References #'s 10 and 11. |
| | Annual review by staff |
| | Removed GCN for Gralise 30-day starter pack (30297) |
| 3/14/2022 | Updated references |
| 2/21/2024 | Updated references |

Page **13** of **13**